Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova

Dumitru Chesov, Nelly Ciobanu, Christoph Lange, Jan Heyckendorf, Valeriu Crudu
European Respiratory Journal 2017 50: 1701340; DOI: 10.1183/13993003.01340-2017
Dumitru Chesov
1Dept of Pneumology and Allergology, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chişinău, Republic of Moldova
6These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dumitru.chesov@usmf.md
Nelly Ciobanu
2National TB Reference Laboratory, Phthisiopneumology Institute “Chiril Draganiuc”, Chişinău, Republic of Moldova
6These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Lange
3Division of Clinical Infectious Diseases, German Center for Infection Research (DZIF), Research Center Borstel, Borstel, Germany
4International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany
5Dept of Medicine, Karolinska Institute, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Heyckendorf
3Division of Clinical Infectious Diseases, German Center for Infection Research (DZIF), Research Center Borstel, Borstel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jan Heyckendorf
Valeriu Crudu
2National TB Reference Laboratory, Phthisiopneumology Institute “Chiril Draganiuc”, Chişinău, Republic of Moldova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

High-dose isoniazid should not be part of a standardised treatment regimen for patients with MDR-TB in Moldova http://ow.ly/zUte30eTtRW

To the Editor:

Since May 2016 the World Health Organization (WHO) has recommended the treatment of multidrug-resistant tuberculosis (MDR-TB) patients with a standardised treatment regimen of 9–12 months duration if patients fulfil specific eligibility criteria [1]. This shorter-course MDR-TB treatment regimen consists of a combination of seven drugs (clofazimine, ethambutol, high-dose isoniazid, kanamycin, moxifloxacin, prothionamide and pyrazinamide) for 4–6 months, followed by four drugs (moxifloxacin, clofazimine, pyrazinamide and ethambutol) for 5 months. It is based on the results from recent observational cohort studies performed in Bangladesh [2], Cameroon [3] and Niger [4] where this or similar treatment regimens led to high cure rates for MDR-TB. Shortly after the WHO proposed the shorter-course MDR-TB regimen, substantial concerns were raised about the applicability of this regimen for patients with MDR-TB in Europe, where many circulating strains of Mycobacterium tuberculosis have additional resistance to 2nd-line anti-tuberculosis (anti-TB) drugs. Based on results from existing databases with comprehensive records of the drug-susceptibility patterns of M. tuberculosis strains in patients with MDR-TB, several groups reported independently that less than 10% of MDR-TB patients from the WHO European Region were likely to be eligible for this regimen [5–8].

We read with interest the correspondence by Heldal et al. [9], which suggested that exclusion criteria should be interpreted more liberally to allow more patients with MDR-TB to be treated with the shorter-course regimen in Europe. We are concerned that such suggestions are being made in the absence of clinical evidence applicable to the geographic region in question and we provide further evidence here as to why this shorter-course treatment regimen should be considered with caution for patients in Europe.

One of the components of the WHO-proposed, shorter-course MDR-TB regimen is high-dose isoniazid. This recommendation is made under the assumption that treatment with 15–20 mg·kg–1 body weight of isoniazid may be effective in M. tuberculosis strains with low-level isoniazid resistance due to mutations in the inhA promotor at positions 8, 15 or 16. There is general consensus that high-level isoniazid resistance due to a mutation in the katG gene at position 315 cannot be overcome by high-dose isoniazid treatment [10]. At the National TB Reference Laboratory of the Phthisiopneumology Institute in Chişinău, Moldova, one of the high-burden countries for MDR-TB in Eastern Europe, we evaluated all the results of molecular drug-resistance testing on M. tuberculosis strains performed by GenoType MTBDRplus v.2 (Hain Lifescience GmbH, Nehren, Germany) line probe assay between 2010 and 2016. This analysis then allowed us to estimate the proportion of patients with MDR-TB that might benefit from high-dose isoniazid therapy as part of the short-course regimen.

From a total of 5368 line probe assay evaluations, 4570 gave valid results (table 1). In 2638 strains, mutations were identified that suggested resistance to both isoniazid and rifampicin, this being indicative of MDR-TB. In 2323 of these 2638 strains (88.1%), a mutation in the katG gene at position 315 was present, suggesting high-level isoniazid resistance. Only 20 out of 2638 strains (0.7%) had a mutation in the inhA promotor alone while in 295 out of 2638 strains (11.2%) the location of a mutation could not be identified by the line probe assay. This data demonstrates that almost 90% of M. tuberculosis strains from patients with MDR-TB in the Republic of Moldova have a high-level of resistance to isoniazid.

View this table:
  • View inline
  • View popup
TABLE 1

Isoniazid and rifampicin resistance profiles in multidrug-resistant tuberculosis (MDR-TB) strains from the Republic of Moldova, 2010–2016

Results from this study strongly suggest that high-dose isoniazid should not be part of a standardised treatment regimen for patients with MDR-TB in the Republic of Moldova or other parts of Europe [11]. A one-size-fits-all solution, like the WHO recommendation for the short-course MDR-TB treatment regimen, is not applicable for many patients outside of Bangladesh, Niger and Cameroon where this regimen has been highly effective. In Europe (and probably in other parts of the world) it is time to move away from standardised treatment regimens towards individualised MDR-TB therapies. For the choice of an individualised MDR-TB treatment regimen, physicians should be guided by drug availability and by the results of comprehensive molecular drug resistance testing (e.g. by line probe assay). Now that these tools are affordable even in the poorest country in Europe, we can move away from solutions based on fixed drug combinations and towards tailor-made therapies (except when all drugs in a treatment combination are novel and the likelihood that M. tuberculosis is resistant to any of the compounds is low).

Disclosures

Supplementary Material

D. Chesov ERJ-01340-2017_Chesov

J. Heyckendorf ERJ-01340-2017_Heyckendorf

C. lange ERJ-01340-2017_Lange

Footnotes

  • Support statement: Christoph Lange and Jan Heyckendorf are supported by the Deutsches Zentrum für Infektionsforschung (DZIF; the German Center for Infection Research).

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received July 4, 2017.
  • Accepted August 5, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Falzon D,
    2. Schünemann HJ,
    3. Harausz E
    , et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Van Deun A,
    2. Aung KJM,
    3. Halim MA
    , et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684–692.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Kuaban C,
    2. Noeske J,
    3. Rieder HL
    , et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517–524.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Piubello A,
    2. Harouna SH,
    3. Souleymane MB
    , et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188–1194.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Lange C,
    2. Duarte R,
    3. Frechet-Jachym M
    , et al. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe. Am J Respir Crit Care Med 2016; 194: 1029–1031.
    OpenUrl
    1. van der Werf MJ,
    2. Hollo V,
    3. Ködmön C
    , et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J 2017; 49: 1601992.
    OpenUrlAbstract/FREE Full Text
    1. Balabanova Y,
    2. Fiebig L,
    3. Ignatyeva O
    , et al. Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule? Thorax 2017; 72: 850–852.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Sotgiu G,
    2. Tiberi S,
    3. D'Ambrosio L
    , et al. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503–1507.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Heldal E,
    2. Van Deun A,
    3. Chiang C-Y
    , et al. Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe. Eur Respir J 2017; 49: 1700228.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Dominguez J,
    2. Boettger EC,
    3. Cirillo D
    , et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis 2016; 20: 24–42.
    OpenUrlCrossRefPubMed
  9. ↵
    1. van Leth F,
    2. Guenther G,
    3. Hoffmann H
    , et al. Reply from the authors of limited benefit of the new shorter MDR-TB regimen in Europe. Am J Respir Crit Care Med 2017; in press [https://doi.org/10.1164/rccm.201705-0995LE].
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 4 Table of Contents
European Respiratory Journal: 50 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova
Dumitru Chesov, Nelly Ciobanu, Christoph Lange, Jan Heyckendorf, Valeriu Crudu
European Respiratory Journal Oct 2017, 50 (4) 1701340; DOI: 10.1183/13993003.01340-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova
Dumitru Chesov, Nelly Ciobanu, Christoph Lange, Jan Heyckendorf, Valeriu Crudu
European Respiratory Journal Oct 2017, 50 (4) 1701340; DOI: 10.1183/13993003.01340-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Identification of prevalent TB disease through screening in migrants
  • Prednisolone plus itraconazole in acute-stage ABPA complicating asthma
  • Prednisolone plus itraconazole in acute-stage ABPA complicating asthma
Show more Agora

Correspondence

  • Prednisolone plus itraconazole in acute-stage ABPA complicating asthma
  • Prednisolone plus itraconazole in acute-stage ABPA complicating asthma
  • Improving alveolar macrophage function through methionine supplementation
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society